April 4, 2003
A research team led by Dr. Virgil Brown from the Emory Lipid Research Laboratory and the VA Medical Center, working closely with Emory Center for AIDS Research investigators, conducted two research studies -- one in a group of 202 HIV-positive women and one in a group of 271 HIV-positive men.
In the study of women, two-thirds had received ARV for at least three months, 25 percent had no therapy in the last three months, and 9 percent had received no ARV therapy. In the study of men, 85 percent had received ARV for more than three months and 15 percent had received no ARV therapy. In both groups, patients treated with either PIs or NNRTIs were more likely to have higher ApoC-III levels than patients on no therapy, and the elevated level of this biomarker corresponded to elevated triglyceride levels on both treatment groups.
"This suggests that patients undergoing HIV therapy have impaired metabolism of triglyceride-rich lipoproteins," said Carlos del Rio, MD, associate professor of medicine at Emory University School of Medicine. "Because a large number of these patients also smoke and/or have diabetes, they are at increased risk of atherosclerosis, heart attack, and stroke." The research, "Elevated ApoC-III Levels Are Associated with Elevated Triglycerides in HIV Positive Men on PI or NNRTI Regimens," was presented in February at the 10th Conference on Retroviruses and Opportunistic Infections in Boston.